A survey of more than 120 endocrinologists, including diabetologists, across the EU, shows many expect to see significant improvements in the outlook for patients with diabetes or diabetic complications over the next three years – and new drugs are largely responsible for their optimism.

However, the study, which was conducted by M3 Global Research in EU countries including the UK, France, Germany, Italy and Spain, also showed that many respondents thought more resources were needed to ensure that patients would be able to access these drugs. 

Experts will be discussing this issue, and more, in a Tweetchat, hosted by PMLiVE and M3, the global provider of technology services in healthcare, next month.

On Thursday September 25 from noon to 1pm (UK time) you will be able to follow the discussion live on Twitter using the hashtag #M3diabetes and join in with your own questions and comments. Alternatively, you can follow the Tweetchat in the embedded Twitter conversation at the bottom of this article.

The one-hour Tweetchat will be split into three sections, with 20 minutes for each of the following questions:

1. What do specialists think about the outlook for patients with diabetes?

2. Where would doctors like to see healthcare organisations focus resources in respect of the management of diabetes in the next few years?

3. How can pharma improve the care of patients with diabetes?

Contributors will include Professor Steve Bain, Assistant Medical Director for Research & Development for ABM University Health Board and Clinical Lead for the Diabetes Research Network, Wales, and Dr Tim Ringrose, CEO of M3 Europe.

With regulators and payors already under pressure to limit access to new treatments in the UK alone, and financial problems within the NHS deepening, pharma needs to become more agile and cost conscious if it is to realise the potential of new drugs. 

But how can pharma work smarter in developing new drugs, from recruiting and managing the clinical trials process, to engaging with target groups in the medical profession, including payors, throughout the product lifecyle? 

#M3diabetes Tweets